

Updated Focused Review of Hematological, Inflammatory, and Lipid Biomarkers in Acute Coronary Syndrome

Keywords

inflammation, prognosis, acute coronary syndrome, biomarker, lipoprotein a

Abstract

At present hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This update focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, Systemic Inflammatory Index (SII), Systemic Inflammatory Response Index (SIRI) and Lipoprotein (a). Novel inflammatory-lipid biomarkers such as hsCRP to high density lipoprotein cholesterol (HDL-C) ratio, Neutrophils to HDL-C ratio, and Monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be a promising clinical tool for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.

Updated Focused Review of Hematological, Inflammatory, and Lipid Biomarkers in Acute Coronary Syndrome

Abstract

At present hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This update focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, Systemic Inflammatory Index (SII), Systemic Inflammatory Response Index (SIRI) and Lipoprotein (a). Novel inflammatory-lipid biomarkers such as hsCRP to high density lipoprotein cholesterol (HDL-C) ratio, Neutrophils to HDL-C ratio, and Monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be a promising clinical tool for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.

Key words: acute coronary syndrome, biomarker, prognosis, inflammation, lipoprotein a.

Introduction

Acute coronary syndromes (ACS) encompass a spectrum of conditions such as acute myocardial infarction (AMI) or unstable angina (UA) [1]. The ACS pathophysiology is highly complex and involves bone marrow activation and inflammation [2].

After AMI human bone marrow increases activity and releases hematopoietic stem and progenitor cells (HSPCs) into circulation [3,4]. Stimulated by hematopoietic growth factors, these progenitor cells can migrate to the spleen where they multiply. The proinflammatory monocytes then leave the spleen and enter atherosclerotic plaques. Once there, they promote inflammation, making the plaques more likely to cause thrombosis, and consequently, AMI [5]. These monocytes also accumulate in injured tissues and participate in wound healing [6].

Recent research reveals the inflammatory signaling networks that connect the brain, autonomic nervous system, bone marrow, and spleen to atherosclerotic plaques and infarcting myocardium. According to Libby et al. these new findings expand the traditional concept of the "cardiovascular continuum" beyond heart and blood vessels by including the nervous system, spleen, and bone marrow in its spectrum [7].

It is known that cardiovascular diseases (CVD) cause endothelial dysfunction, leakage, vascular fibrosis, and angiogenesis in the bone marrow's vascular niche, leading to increased hematopoiesis and the production of inflammatory leukocytes [8]. Patients with ACS who exhibit elevated levels of baseline inflammatory markers are at increased risk of adverse cardiovascular events, particularly cardiovascular death.

Hematological indices are simple, inexpensive and easily available biomarkers derived from the complete blood count [2]. Inflammatory and lipid biomarkers can further improve the selection of patients with ACS who would most likely benefit from anti-inflammatory therapy [9]. In this update review we have focused on data published since our previous review in 2017 to the present [2]. Figure 1 illustrates the major categories of these biomarkers and their clinical role in the context of ACS.




Figure 1. Summary of biomarker categories and their clinical utility in the context of ACS.

ACS – acute coronary syndrome, WBC: white blood cell count; NLR – neutrophil to lymphocyte ratio; PLR – platelet-to-lymphocyte ratio; MHR - monocyte-to-HDL ratio; NHR - Neutrophils to HDL-C ratio; CHR- High-sensitivity CRP to HDL-C ratio; SII - systemic immune-inflammation index; SIRI - systemic inflammation response index

White Blood Cell Count (WBC)

Leukocytes play a major role in the pathophysiology of ACS. The recognition of leukocytosis as a response to MI dates back several decades. They coordinate the mechanisms of innate immunity [10]. Polymorphonuclear leukocytes can promote endothelial damage during superficial erosion [11]. In a large prospectively followed cohort of patients at a high risk of incident coronary events, the WBC count was identified as an independent predictor of death/MI [12]. In the multicenter, prospective, observational PARIS study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry) increased WBC was an independent predictor of major adverse cardiovascular events (MACE), which was linked to cardiac death, stent thrombosis, spontaneous myocardial infarction (MI), or target lesion revascularization at a 24-month follow-up after percutaneous coronary intervention (PCI) [13].

Neutrophil to Lymphocyte Ratio (NLR)

Neutrophils have demonstrated important functions during cardiovascular inflammation and repair. Neutrophils can participate in superficial plaque erosion or fibrous cap rupture [11]. These cells accelerate all stages of atherosclerosis by fostering monocyte recruitment and macrophage activation [14]. Neutrophil secretory products not only attract but also activate macrophages. Activated neutrophils release neutrophil extracellular traps (NETs) composed of chromatin via NETosis, a cell-death program different from apoptosis or necrosis [15]. Mangold et al. detected NETs throughout coronary thrombi, serving as a primary scaffold for platelets, erythrocytes and fibrin [16].

Following ischemic injury, there is an initial scarcity of lymphocytes within the infarct, which prompts their rapid proliferation within the adjacent draining lymph nodes. [17]. The absolute lymphocyte count is negatively associated with CV events [17].

Among the leukocyte subtypes studied there, the neutrophil count, lymphocyte count, and NLR were the significant independent predictors of death or MI. However, the markers mentioned along with NLR appeared to have a greater predictive value [12].

NLR is an easily obtained inflammatory biomarker whose effectiveness as a predictor of cardiovascular risk in primary and secondary prevention scenarios has been supported by academic research [18]. It is still unknown whether NLR (independent of hsCRP) is linked to atherosclerotic events. Moreover, while the independent prognostic significance of NLR has been established across various diseases, determining its precise normal cut-off value remains a subject of ongoing debate [19].

In all five contemporary randomized trials (JUPITER, CANTOS, SPIRE-1, SPIRE-2, and CIRT), NLR consistently served as a predictor of future cardiovascular events and all-cause mortality [18]. The advantage of NLR index is that it remains constant during subsequent measurements, increasing its potential as a useful biomarker in clinical practice.

The data on drug response to canakinumab - the interleukin-1 β inhibitor suggest the potential usage of NLR to monitor the effectiveness of emerging anti-inflammatory strategies for atherothrombosis [18].

In the meta-analysis of 90 studies based on the data of 45,990 participants, Pruc et al. showed that NLR was associated with mortality in ACS, with the survivors having lower results (3.67 ± 2.72 vs. 5.56 ± 3.93) [20]. The subanalysis showed that NLR differed in ST-segment elevation myocardial infarction (STEMI) among the survivors (4.28 ± 3.24 vs. 6.79 ± 3.98). Among the ACS patients with MACE versus those without MACE, NLR was 6.29 ± 4.89 vs 3.82 ± 4.12 [20].

Another meta-analysis indicated that the pretreatment NLR value of 5.0 might be a cut-off value for ACS risk [21]. The combination of d-dimer and NLR was associated with long-term MACEs in ACS patients who underwent PCI [22]. Interestingly, in a Korean nationwide prospective cohort, the combination of NLR and anemia on admission was strongly associated with all-cause mortality after STEMI [23].

Increased NLR was independently associated with the risk of contrast-induced nephropathy (CIN) in the NSTEMI-ACS patients treated by PCI [24]. In another study, elevated NLR, but not

platelet to lymphocyte ratio (PLR) was an independent predictor of CIN among the patients with AMI [25]. However, higher NLR and PLR in post-AMI patients were the independent predictors of left ventricular thrombosis resolution failure only amongst the patients who did not undergo PCI [26].

The patients with ACS who underwent PCI despite receiving aspirin (ASA) and ticagrelor as dual antiplatelet therapy (DAPT) turned out to have a notably elevated inadequate platelet inhibition when NLR exhibited higher values [27]. Long-term mortality and the likelihood of experiencing recurrent major ischemic events were also found to be correlated with NLR.

Platelet to Lymphocyte Ratio

PLR has been linked to heightened inflammatory activity and a significant pro-thrombotic state. Higher PLR was an independent risk factor for the development of CIN in patients with STEMI undergoing PCI [28]. Oylumlu M., et al. demonstrated that a high PLR level is an independent predictor of long-term poor prognosis in ACS patients [29]. Meta-analysis revealed that PLR is a promising biomarker in predicting both in-hospital and long-term poor prognosis in ACS patients [30]. A meta-analysis including 11 cohort studies and a total of 12,619 patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) demonstrated that elevated preprocedural PLR was independently associated with a significantly increased risk of in-hospital MACE, cardiac mortality, all-cause mortality, and the no-reflow phenomenon. Furthermore, elevated PLR was a significant predictor of MACE and all-cause mortality during long-term follow-up periods extending up to 82 months post-discharge. [31].

Neutrophils to HDL-C ratio (NHR)

NHR is a novel marker that reflects inflammation and lipid metabolic disorders. Kou et al. showed that NHR was associated with coronary artery stenosis and worked as an independent predictor of coronary artery disease (CAD) [32].

Ren et al. demonstrated that NHR was higher in the patients with diabetes mellitus type 2 (T2DM) combined with ACS than in the T2DM patients without ACS [33]. The same study also showed that the diagnostic power of NHR was stronger in the ACS patients with elevated ST-segment (STE-ACS) than in the non-ST-segment ACS patients (NSTEMI-ACS) ($p < 0.001$) [33].

Huang et al. demonstrated that NHR might have a predictive value for prognosis in long-term mortality and recurrent MI in older patients with AMI [34]. The study of Chen et al. proved that NHR was independently associated with an increased incidence of in-hospital MACE in STEMI patients treated with PCI [35]. It demonstrated that NHR outperformed other hematological and lipid indices, including Monocyte to HDL-C ratio (MHR) and LDL-C/HDL-C, in predicting the prognosis for patients with AMI [35].

hsCRP to HDL-C ratio (CHR)

The use of inflammatory markers in combination with lipid markers may improve the prediction of cardiovascular events to a greater extent than either marker alone.

According to Gao et al., high CHR is a significant risk factor for CVD, stroke, and heart problems [36]. The study of Luo et al. showed that CHR was an independent predictor of severe CAD with better diagnostic performance than NLR [37].

In the study of Tang et al. HDL levels could not reflect HDL's functional status in patients with CAD. CAD patients with higher hsCRP levels had larger HDL particles (HDL1) and less smaller HDL particles (HDL4) [38]. In the another prospective cohort study involving 3,260 patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) elevated CHR was independent risk factor for long-term all-cause mortality, cardiac mortality and MACEs [39].

These studies underscore the significance of the CHR as a composite marker reflecting the balance between pro-inflammatory and anti-atherogenic factors in cardiovascular health. An elevated CHR is associated with increased risk and severity of ACS and related adverse outcomes.

Monocyte to HDL-C ratio

MHR was an independent predictor of CAD severity and future cardiovascular events in patients with ACS [40].

A high value of MHR among the STEMI patients who underwent primary PCI was associated with higher in-hospital mortality and MACE [41]. The study of Guo et al. demonstrated that HDL-C-related inflammatory indices (monocyte-to-HDL-C ratio, neutrophil-to-HDL-C ratio and lymphocyte-to-HDL-C ratio) independently predicted repeated revascularization after coronary drug-eluting stenting. MHR exhibited a dose-response relationship and showed a linear correlation with the incidence of repeat revascularization [42]. The meta-analysis incorporated eight studies comprising a total of 6,480 patients diagnosed with acute coronary syndrome (ACS) [43]. The results indicated that an elevated MHR was significantly associated with an increased risk of major adverse cardiovascular events (MACE) (Risk Ratio [RR]: 1.65) and all-cause mortality (RR: 2.61). Importantly, the prognostic significance of MHR was consistent across both short-term (in-hospital) and long-term (beyond 6 months) follow-up periods [43].

Systemic Immune Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI)

Two innovative inflammatory markers have recently been introduced into clinical practice: the Systemic Immune Inflammation Index (SII) and the System Inflammation Response Index (SIRI). These markers are composed of platelet counts and three subtypes of leukocytes. The SIRI index measures inflammation by combining the absolute counts of three types of inflammatory cells: neutrophils, monocytes, and lymphocytes [44]. SII is defined as $\text{platelet count} \times \text{neutrophil count} / \text{lymphocyte count}$ [44]. They might be linked to the risk of overall stroke and all-cause mortality [44]. SIRI, but not SII, has been positively associated with MI incidence [44]. This association was significant only in individuals under the age of 60. It was found that both SII and SIRI exert effects that are independent of C-reactive protein (CRP) levels [44].

Among the five lymphocyte-based inflammatory indices including PLR, NLR, monocyte-lymphocyte ratio (MLR), SII and SIRI were significantly and independently associated with MACE in the ACS patients who underwent PCI [45]. In another study, SIRI was a strong and independent risk factor for MACE in patients with ACS undergoing PCI [46].

SII and SIRI were higher among the patients diagnosed with STEMI, NSTEMI and UA compared to those with stable CAD. The highest SIRI values were observed in three-vessel CAD [47]. Fan et al. found that a higher systemic immune-inflammatory index (SII) and derived NLR (dNLR) were independently associated with a higher risk of developing all-cause mortality and rehospitalization for severe heart failure in patients with ACS undergoing PCI [48].

Lipoprotein (a)

Lp(a) is a lipoprotein composed of a low-density lipoprotein (LDL)-like particle and a specific apolipoprotein(a). **It is mostly genetically determined (70-90%).** Lp(a) can be used as a marker for residual cardiovascular risk in patients with ACS. Epidemiologic and genetic studies support a causal association between Lp(a) concentration and cardiovascular outcomes [49]. Lp(a) has pro-inflammatory and pro-atherosclerotic properties, which may partly relate to the oxidized phospholipids carried by Lp(a). The widely used cardiovascular risk assessment tools for primary prevention do not incorporate Lp(a) levels. However, in the context of primary prevention, high levels of Lp(a) are linked to various atherosclerotic cardiovascular disease outcomes, aortic valve stenosis, and both cardiovascular and all-cause mortality [50,51,52,54]. Elevated levels of Lp(a) are recognized as an independent risk factor for ACS, with particular clinical relevance in individuals who present with normal lipid profiles or experience premature and recurrent cardiovascular events despite receiving optimal medical therapy. Moreover Lp (a) was independently associated with ACS in younger individuals (<45 years) and high Lp(a) levels increased by ~3folds the risk for ACS [53].

Measurement of Lp(a) during the acute phase of ACS is not recommended, as circulating levels are frequently elevated due to the acute-phase response [54]. However, assessment of Lp(a) at the time of hospital discharge or during early follow-up is of significant clinical importance. Such evaluation may provide prognostic insight and support risk stratification efforts aimed at preventing recurrent cardiovascular events [54]. In 2021, for the first time, the Polish guidelines issued by six scientific societies on managing lipid disorders incorporated an elevated Lp(a) concentration of over 50 mg/dl (125 nmol/l) as an additional criterion for identifying extremely high cardiovascular risk in patients with diabetes following ACS [55]. **Polish guidelines recommend Lp(a) measurement in all patients with Atherosclerotic Cardiovascular Disease (ASCVD) [49].** Emerging therapies specifically targeting Lp(a), notably antisense oligonucleotides such as pelacarsen and small interfering RNA (siRNA) agents including olpasiran and lepodisiran, represent a significant advancement in the therapeutic landscape for managing cardiovascular risk in individuals with elevated Lp(a) concentrations [56].

Future perspectives:

Artificial intelligence

Artificial intelligence (AI) is an essential element of clinical decision-aid systems.

In the study by Yilmaz et al. a thorough data analysis was conducted, employing the Light Gradient Boosting Machine (LGBM) model along with explainable artificial intelligence (XAI) to explore the potential hematological predictors of AMI [56]. The model which included the 10 most important hematological parameters achieved 83% and 74% accuracy for predicting AMI and distinguishing subgroups of AMI (STEMI and NSTEMI), respectively. The analysis of the AMI output reveals that the features of neutrophils, WBC, platelet distribution width (PDW), and basophils are of utmost significance in diagnosing AMI patients [57].

Another study tried to develop risk models based on widely available, simple hematologic predictors which included hematocrit, hemoglobin concentration, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), mean platelet volume (MPV), platelet count (PLT), red blood cell count (RBC), and red cell volume distribution width (RDW) [58]. The above hematologic indices had a predictive value for cardiovascular outcomes above and beyond traditional risk factors. According to Truslow et al. hematology-based models modestly predict incidents of ACSs beyond what was possible using only age and prior diagnoses [58]. It was suggested that a strategy combining age, and hematologic indices may be more accurate in predicting incident ACS [58].

Genetics

The Mendelian randomization study utilizing the data from the UK Biobank and the Japan Biobank revealed that the RBC count, hemoglobin levels, hematocrit, and uric acid levels independently influence the CAD risk, independently of traditional cardiometabolic factors [59]. It was proposed that targeting the physiology of red blood cells and managing uric acid levels could serve as potential interventions for preventing CAD [59].

MPV is the primary measure of platelet size and is strongly associated with platelet reactivity. There are conflicting results concerning the relationship between MPV and ACS. Some studies have demonstrated a significant association between MPV and AMI, whereas most studies have not found such a relationship [60,61]. The research of Kunicki et al. indicated that MPV is the most significant factor influencing the variation in levels of platelet integrin $\alpha\text{IIb}\beta 3$ (a receptor for fibrinogen and von Willebrand factor), both in healthy individuals and patients with ACS [62]. Due to the increased activity of larger platelets, MPV serves as a reliable indicator of risk for adverse outcomes in ACS [62].

Discussion

The pathophysiology of inflammation and atherosclerosis is highly complex. Bone marrow activation and inflammation, whether chronic or acute, might be an undermined risk factor. Many patients with AMI do not have elevated LDL-C levels but do show signs of increased inflammation. According to Ridker, the patients who experienced AMI are more likely to have residual inflammation rather than elevated LDL-C levels [63]. The CANTOS study provides evidence supporting this hypothesis. It explains that inhibiting the progression of inflammation led to a significantly lower rate of recurrent cardiovascular events independent

of lipid-level reduction [64]. The low-density lipoprotein (LDL) should be considered a substrate for the lipid core. The danger associated with this fraction lies in its susceptibility to oxidation (only when modified in this way does the particle have a causal relationship with atherosclerotic plaque formation). The susceptibility of LDL to oxidation is directly linked to an increased redox potential, which may result from heightened inflammatory states. In light of this paradigm, anti-atherosclerotic treatment should focus on reducing inflammation and decreasing the concentration of substrates involved in plaque formation.

The increased movement of leukocytes to the plaque after AMI relies on the movement of progenitor cells from bone marrow. This process precedes extramedullary hematopoiesis and contributes to the continuous build-up of leukocytes within the atherosclerotic lesion [5].

Hematological indices were chosen given that numerous factors contributing to chronic diseases like CVD are systemic and may manifest themselves across various tissue types [58]. Furthermore, hematological indices may be utilized to create AI-based cardiovascular risk models from the clinical electronic health record data [58]. The findings from these studies can pave the way for more targeted anti-inflammatory therapies and guide future drug development strategies [18].

Most recent studies also show direct head-to-head comparisons of hematological indices (RDW, MPV, NLR, PLR, MHR) for predicting the mortality risk in ACS patients [65,66]. According to Sigrirci, NLR had the highest area in the receiver operating characteristic curve. NLR can be utilized to predict in-hospital mortality in STEMI patients [64]. By contrast, RDW and the MHR are superior hematological indices for forecasting long-term mortality after STEMI compared to other common biomarkers [65]. Interestingly, in another study, Li et al. showed that novel parameters SII and SIRI are more comprehensive than PLR, NLR and MLR given that they combine three types of inflammatory cells [66]. SIRI was considered more successful in predicting MACE than PLR, NLR, MLR, and SII [66].

Limitations

Given that NLR is derived from the ratio of two absolute cell counts, any physiological condition that selectively impacts neutrophils or lymphocytes will inevitably affect NLR. These conditions comprise acute hematological malignancies, inflammation, immune deficiencies and the admission of immunomodulatory medications [18]. For example, lipid-lowering therapies had no significant effect on NLR, while methotrexate increased NLR while canakinumab decreased it [18]. NLR might also increase in response to physiological stress, given that glucocorticoids induce relative neutrophilia and lymphopenia. The available data do not suffice to determine whether elevated NLR plays a role in atherosclerotic events.

The studies concerning hematological indices often have a retrospective design, which may undermine the conclusions. Most researchers chose to measure the parameters only at admission, rather than taking multiple repeated measurements. Another limitation is that some research was carried out in a single center and the study population size was small, so multicenter and large-scale studies are needed to verify these conclusions.

Conclusions

The prognostic significance of inflammatory markers in cardiovascular diseases has gained particular prominence following the publication of the CANTOS study, which clinically validated Ridker's hypothesis regarding the inflammatory etiology of atherosclerosis [64]. This study has also expanded the former understanding of cardiovascular risk based solely on assessing concentrations of substrates involved in forming atherosclerotic plaque.

There is a great demand for an easily available, noninvasive hematological marker for prognosis in ACS patients. Such a marker would help identify high-risk cardiovascular patients for secondary prevention and allow individual therapy adjustments. Numerous studies have highlighted the importance of hematological indices in forming the prognosis of ACS, as demonstrated earlier. Recent advancements in AI will enable the development of models that aid the diagnosis, treatment, and follow-up of patients with ACS. By examining easily available hematological indices, healthcare providers will be better equipped to make well-informed decisions and deliver improved care to a diverse patient population. A summary of their benefits, limitations, and research gaps is presented in Table 1.

Table 1. Summary of Biomarker Categories in ACS: Benefits, Limitations, and Future Perspectives.

Biomarker Category	Benefits / Strengths	Limitations	Current Gaps	Future Research Directions
Hematological Inflammatory Indices				
WBC, NLR, PLR	<ul style="list-style-type: none"> - Easily accessible from routine CBC - Cost-effective - Reflect inflammatory burden and immune activation 	<ul style="list-style-type: none"> - Lack specificity for cardiovascular diseases - Influenced by comorbid conditions (e.g., infection, cancer) 	<ul style="list-style-type: none"> - No universal thresholds for risk stratification - Heterogeneous cut-offs across studies 	<ul style="list-style-type: none"> - Standardization of cut-off values - Validation in prospective, multi-center ACS cohorts
Lipid-Inflammation Ratios				
CHR, NHR, MHR	<ul style="list-style-type: none"> - Combine pro-atherogenic inflammation with anti-atherogenic lipid markers - May reflect 	<ul style="list-style-type: none"> - Dependent on accurate lipid measurements - Not routinely calculated in clinical practice 	<ul style="list-style-type: none"> - Limited validation in acute vs. stable disease - Lack of clinical interpretability guidance 	<ul style="list-style-type: none"> - Integration into composite risk models - Longitudinal studies for prognostic validation

	residual risk in treated patients			
Lipid Biomarkers				
Lipoprotein(a)	- Genetically determined - It is mostly genetically determined (70-90%) - Although not routinely performed in clinical practice, Lp(a) testing is becoming increasingly accessible - Independent predictor of long-term CV risk - May indicate inherited risk	- Limited acute-phase relevance - Due to acute-phase elevation, Lp(a) should not be measured during ACS, but assessment at discharge or early follow-up is valuable for risk stratification - Testing not routinely available, - Treatment options evolving	- Role in acute settings underexplored - Absence of standardized screening criteria - Educational gaps among clinicians - Long-term safety and therapy monitoring remain undefined	- Evaluation of new therapeutic agents - Risk stratification in primary prevention - Universal screening for Lp(a) has been recently adopted in Poland through the My Health program, which includes cascade testing of young adults to identify affected family members.
Emerging Composite Indices				
SII, SIRI	- Integrate multiple immune pathways - May offer superior predictive value over single indices	- Complex calculation - Not routinely included in lab reports	- Limited large-scale validation - Unclear clinical applicability in ACS	- Prospective cohort studies - Comparative effectiveness research with traditional markers

Abbreviations : CBC – complete blood count; ACS- acute coronary syndrome; WBC: white blood cell count; NLR – neutrophil to lymphocyte ratio; PLR – platelet-to-lymphocyte ratio; MHR - monocyte-to-HDL ratio;; NHR - Neutrophils to HDL-C ratio; CHR- High-sensitivity CRP to HDL-C ratio; SII - systemic immune-inflammation index; SIRI - systemic inflammation response index

References:

- 1) Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J*. 2023;44(38):3720-3826.
- 2) Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The Role of Hematological Indices in Patients with Acute Coronary Syndrome. *Dis Markers*. 2017;2017:3041565.
- 3) Assmus B, Iwasaki M, Schächinger V, Roex T, Koyanagi M, Iekushi K, et al. Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. *Eur Heart J*. 2012; 33(15): 1911-1919.
- 4) Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. *Blood* 2005; 105(1): 199-206.
- 5) Libby P, Nahrendorf M, Swirski FK. Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum". *J Am Coll Cardiol*. 2016;67(9):1091-1103.
- 6) Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. *Science*. 2009;325(5940):612-6.
- 7) Libby P, King K. Biomarkers: A Challenging Conundrum in Cardiovascular Disease. *Arterioscler Thromb Vasc Biol*. 2015;35(12):2491-5.
- 8) Rohde D, Vandoorne K, Lee IH, Grune J, Zhang S, McAlpine CS, et al. Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. *Nat Cardiovasc Res*. 2022;1(1):28-44.
- 9) Matter MA, Paneni F, Libby P, Frantz S, Stähli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. *Eur Heart J*. 2024;45(2):89-103.
- 10) Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. *Science*. 2013;339(6116):161-6.
- 11) Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes: the "vulnerable plaque" and superficial erosion. *Circ Res*. 2019, 124(1), 150-160.
- 12) Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? *J Am Coll Cardiol*. 2005;45(10):1638-43.
- 13) Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White blood cell count and major adverse cardiovascular events after percutaneous coronary intervention in the contemporary era: insights from the PARIS study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). *Circ Cardiovasc Interv*. 2017; 10(9), e004981.
- 14) Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. *Nat Rev Cardiol*. 2020;17(6):327-340.

- 15) Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol.* 2007;176(2):231-41.
- 16) Mangold A, Alias S, Scherz T, Hofbauer M, Jakowitsch J, Panzenböck A, et al. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. *Circ Res* 2015, 116(7), 1182-1192.
- 17) Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, et al. Activation of CD4⁺ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. *Circulation.* 2012;125:1652
- 18) Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. *Eur Heart J.* 2021; 42(9): 896-903.
- 19) Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? *BMC Res Notes.* 2017;10:12.
- 20) Pruc M, Kubica J, Banach M, Swieczkowski D, Rafique Z, Peacock WF, et al. Diagnostic and prognostic performance of neutrophil-to-lymphocyte ratio in acute coronary syndromes: A meta-analysis of 90 studies including 45 990 patients. *Pol Heart J.* 2024;82(3):276-284.
- 21) Dong CH, Wang ZM, Chen SY. Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary syndrome: A systematic review and meta-analysis. *Clin Biochem.* 2018; 52: 131-136.
- 22) Gu LF, Gu J, Wang SB, Wang H, Wang H, Wang YX, Xue Y, et al. Combination of D-dimer level and neutrophil to lymphocyte ratio predicts long-term clinical outcomes in acute coronary syndrome after percutaneous coronary intervention. *Cardiol J.* 2023;30(4):576-586.
- 23) Cho KH, Shin MH, Kim MC, Sim DS, Hong YJ, Kim JH, et al. Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) Investigators. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio Combined With Anemia in Patients With ST-Segment Elevation Myocardial Infarction: A Nationwide Prospective Cohort Study. *J Lipid Atheroscler.* 2022;11(2):147-160.
- 24) Kurtul A, Yarlioglues M, Duran M, Murat SN. Association of neutrophil-to-lymphocyte ratio with contrast-induced nephropathy in patients with non-ST-elevation acute coronary syndrome treated with percutaneous coronary intervention. *Heart Lung Circ.* 2016; 25(7): 683-690.
- 25) Butt K, D'Souza J, Yuan C, Jayakumaran J, Nguyen M, Butt HI, et al. Correlation of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary interventions. *Cureus* 2020; 12(12).
- 26) Sia CH, Leow AST, Tan BYQ, Low CJ, Kaur R, Yeo TC, et al. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention. *Thromb Res.* 2020;194:16-20.
- 27) Verdoia M, Nardin M, Gioscia R, Negro F, Marcolongo M, Suryapranata H, et al. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet

inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor. *Vasc Pharm*. 2020; 132: 106765.


- 28) Sun XP, Li J, Zhu WW, Li DB, Chen H, Li HW, et al. Platelet to lymphocyte ratio predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Angiology* 2018; 69(1): 71-78.
- 29) Oylumlu M, Oylumlu M, Arslan B, Polat N, Özbek M, Demir M, et al. Platelet-to-lymphocyte ratio is a predictor of long-term mortality in patients with acute coronary syndrome. *Adv Interv Cardiol*. 2020;16(2):170-176.
- 30) Li W, Liu Q, Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. *Sci Rep*. 2017;7:40426.
- 31) Dong G, Huang A, Liu L. Platelet-to-lymphocyte ratio and prognosis in STEMI: A meta-analysis. *Eur J Clin Invest*. 2021 Mar;51(3):e13386.
- 32) Kou T, Luo H, Yin L. Relationship between neutrophils to HDL-C ratio and severity of coronary stenosis. *BMC Cardiovasc Disord*. 2021;21(1):127.
- 33) Ren H, Zhu B, Zhao Z, Li Y, Deng G, Wang Z, et al. Neutrophil to high-density lipoprotein cholesterol ratio as the risk mark in patients with type 2 diabetes combined with acute coronary syndrome: a cross-sectional study. *Sci Rep*. 2023;13(1):7836.
- 34) Huang JB, Chen YS, Ji HY, Xie WM, Jiang J, Ran LS, et al. Neutrophil to high-density lipoprotein ratio has a superior prognostic value in elderly patients with acute myocardial infarction: a comparison study. *Lipids Health Dis*. 2020; 19: 1–12.
- 35) Chen Y, Jiang D, Tao H, Ge P, Duan Q. Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study. *BMC Cardiovasc Disord*. 2022; 22: 434.
- 36) Gao Y, Wang M, Wang R, Jiang J, Hu Y, Wang W, et al. The predictive value of the hs-CRP/HDL-C ratio, an inflammation-lipid composite marker, for cardiovascular disease in middle-aged and elderly people: evidence from a large national cohort study. *Lipids Health Dis*. 2024; 23(1): 66.
- 37) Luo H, Kou T, Yin L. High-Sensitivity C-Reactive Protein to HDL-C Ratio A Predictor of Coronary Artery Disease. *Int Heart J*. 2021; 62(6): 1221-1229.
- 38) Tang X, Mao L, Chen J, Zhang T, Weng S, Guo X, et al. High-sensitivity CRP may be a marker of HDL dysfunction and remodeling in patients with acute coronary syndrome. *Sci Rep*. 2021; **11**: 11444.
- 39) Dai XY, Xue ZK, Wang XW, Chen KY, Hu ST, Tse G, Rha SW, Liu T. High-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio predicts long-term adverse outcomes in patients who underwent percutaneous coronary intervention: A prospective cohort study. *Clin Exp Pharmacol Physiol*. 2024 Nov;51(11):e13919
- 40) Cetin MS, Ozcan Cetin EH, Kalender E, Aydin S, Topaloglu S, Kisacik HL, et al. Monocyte to HDL Cholesterol Ratio Predicts Coronary Artery Disease Severity and Future Major Cardiovascular Adverse Events in Acute Coronary Syndrome. *Heart Lung Circ*. 2016;25(11):1077-1086.

- 41) Villanueva DLE, Tiongson MD, Ramos JD, Llanes EJ. Monocyte to High-Density Lipoprotein Ratio (MHR) as a predictor of mortality and Major Adverse Cardiovascular Events (MACE) among ST Elevation Myocardial Infarction (STEMI) patients undergoing primary percutaneous coronary intervention: a meta-analysis. *Lipids Health Dis.* 2020;19(1): 55.
- 42) Guo X, Shen R, Su Y, Ma L. High-Density Lipoprotein-Related Inflammatory Indices Predict Repeat Revascularization in Coronary Drug-Eluting Stenting. *Biomark Med.* 2023; 17(22): 959–969.
- 43) Sun M, Zhao D, Zhang Y, Zhai Y, Ye M, Wang X, Zheng L, Wang L. Prognostic Utility of Monocyte to High-Density Lipoprotein Ratio in Patients With Acute Coronary Syndrome: A Meta-Analysis. *Am J Med Sci.* 2020 May;359(5):281-286.
- 44) Jin Z, Wu Q, Chen S, Gao J, Li X, Zhang X, et al. The Associations of Two Novel Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals. *J Inflamm Res.* 2021;14:131-140.
- 45) Li Q, Ma X, Shao Q, Yang Z, Wang Y, Gao F, et al. Prognostic impact of multiple lymphocyte-based inflammatory indices in acute coronary syndrome patients. *Front Cardiovasc Med* 2022; 9:811790.
- 46) Han K, Shi D, Yang L, Wang Z, Li Y, Gao F, et al. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Ann Med.* 2022; 54(1):1667-1677.
- 47) Dziedzic EA, Gąsior JS, Tuzimek A, Paleczny J, Junka A, Dąbrowski M, et al. Investigation of the Associations of Novel Inflammatory Biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)-With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence. *Int J Mol Sci.* 2022;23(17):9553.
- 48) Fan W, Zhang Y, Gao X, Liu Y, Shi F, Liu J, et al. The Prognostic Value of a Derived Neutrophil-Lymphocyte Ratio in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. *Clin Appl Thromb Hemost.* 2021;27:10760296211034579.
- 49) Sosnowska B, Stepinska J, Mitkowski P, Bielecka-Dabrowa A, Bobrowska B, Budzianowski J, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein (a) levels. *Arch Med Sci.* 2024;20(1):8-27.
- 50) Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. *JACC Heart Fail* 2016;4:78–87. doi:10.1016/j.jchf.2015.08.006
- 51) Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. *Eur Heart J* 2019;40:2760–2770. doi:10.1093/eurheartj/ehy902
- 52) Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, et al. Lipoprotein (a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. *J Am Coll Cardiol*, 2024; 83(9): 873-886.

- 53) Rallidis LS, Pavlakis G, Foscolou A, Kotakos C, Katsimardos A, Drosatos A, Zolindaki M, Panagiotakos DB. High levels of lipoprotein (a) and premature acute coronary syndrome. *Atherosclerosis*. 2018 Feb;269:29-34
- 54) Sosnowska B, Toth PP, Razavi AC, Remaley AT, Blumenthal RS, Banach M. 2024: The year in cardiovascular disease - the year of lipoprotein(a). *Research advances and new findings. Arch Med Sci*. 2025 Feb 22;21(2):355-373. doi: 10.5114/aoms/202213. PMID: 40395905; PMCID: PMC12087327.
- 55) Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, et al. PoLA/CFPiP/ PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. *Arch Med Sci* 2021; 17: 1447-547.
- 56) Banach M, Surma S. A look to the past - what has had the biggest impact on lipids in the last four decades? A personal perspective. *Arch Med Sci*. 2023 May 16;19(3):559-564.
- 57) Yilmaz R, Yagin FH, Raza A, Colak C, Akinci TC. Assessment of Hematological Predictors via Explainable Artificial Intelligence in the Prediction of Acute Myocardial Infarction. *IEEE Access*. 2023.
- 58) Truslow JG, Goto S, Homilius M, Mow C, Higgins JM, MacRae CA, et al. Cardiovascular risk assessment using artificial intelligence-enabled event adjudication and hematologic predictors. *Circ Cardiovasc Qual Outcomes*. 2022; 15(6): e008007.
- 59) Wang K, Shi X, Zhu Z, Hao X, Chen L, Cheng S, et al. Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations. *Genome Med*. 2022; 14(1): 63.
- 60) Kiliçli-Camur N, Demirtunç R, Konuralp C, Eskiser A, Başaran Y. Could mean platelet volume be a predictive marker for acute myocardial infarction? *Med Sci Monit*. 2005;11(8):CR387-92.
- 61) Yilmaz MB, Cihan G, Guray Y, Guray U, Kisacik HL, Sasmaz H, et al. Role of mean platelet volume in triagging acute coronary syndromes. *J Thromb Thrombolysis*. 2008;26:49–54.
- 62) Kunicki TJ, Williams SA, Nugent DJ, Yeager M. Mean platelet volume and integrin alleles correlate with levels of integrins $\alpha\text{IIb}\beta\text{3}$ and $\alpha\text{2}\beta\text{1}$ in acute coronary syndrome patients and normal subjects. *Arteriosclerosis, thrombosis, and vascular biology* 2012; 32(1): 147-152.
- 63) Ridker, P. M. How common is residual inflammatory risk?. *Circ Res*. 2017; 120(4): 617-619.
- 64) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med*. 2017 Sep 21;377(12):1119-1131.
- 65) Sigirci S, Ser ÖS, Keskin K, Yildiz SS, Gurdal A, Kilickesmez KO. Comparing the Prognostic Value of Hematological Indices in Patients With ST Segment Elevation Myocardial Infarction: "A Head to Head" Analysis. *Angiology*. 2021;72(4):348-354.
- 66) Li Q, Ma X, Shao Q, Yang Z, Wang Y, Gao F, et al. Prognostic impact of multiple lymphocyte-based inflammatory indices in acute coronary syndrome patients. *Front Cardiovasc Med*. 2022; 9: 811790.

Abbreviations:

ACS - Acute Coronary Syndrome, AMI - Acute Myocardial Infarction, UA - Unstable Angina, HSPCs - Hematopoietic Stem and Progenitor Cells, CVD - Cardiovascular Diseases, WBC - White Blood Cell Count, MACE - Major Adverse Cardiovascular Events, PCI - Percutaneous Coronary Intervention, NETs - Neutrophil Extracellular Traps, ALC - Absolute Lymphocyte Count, NLR - Neutrophil to Lymphocyte Ratio, STEMI - ST-Segment Elevation Myocardial Infarction, DAPT - Dual Antiplatelet Therapy, PLR - Platelet to Lymphocyte Ratio, NHR - Neutrophils to HDL-C Ratio, CAD - Coronary Artery Disease, T2DM - Diabetes Mellitus Type 2, STE-ACS - ACS Patients with Elevated ST-Segment, NSTEMI-ACS - Non-ST-Segment Elevation ACS Patients, CHR - hsCRP to HDL Ratio, MHR - Monocyte to HDL Cholesterol Ratio, SII - Systemic Immune Inflammation Index, SIRI - Systemic Inflammation Response Index, CRP - C-Reactive Protein, MLR - Monocyte-Lymphocyte Ratio, Lp(a) - Lipoprotein (a), AI - Artificial Intelligence, LGBM - Light Gradient Boosting Machine, XAI - Explainable Artificial Intelligence, MCH - Mean Corpuscular Hemoglobin, MCHC - Mean Corpuscular Hemoglobin Concentration, MCV - Mean Corpuscular Volume, MPV - Mean Platelet Volume, PLT - Platelet Count, RBC - Red Blood Cell Count, RDW - Red Cell Volume Distribution Width, LDL - Low-Density Lipoprotein.




Preprint

Table 1. Summary of Biomarker Categories in ACS: Benefits, Limitations, and Future Perspectives.

Biomarker Category	Benefits / Strengths	Limitations	Current Gaps	Future Research Directions
Hematological Inflammatory Indices				
WBC, NLR, PLR	<ul style="list-style-type: none"> - Easily accessible from routine CBC - Cost-effective - Reflect inflammatory burden and immune activation 	<ul style="list-style-type: none"> - Lack specificity for cardiovascular diseases - Influenced by comorbid conditions (e.g., infection, cancer) 	<ul style="list-style-type: none"> - No universal thresholds for risk stratification - Heterogeneous cut-offs across studies 	<ul style="list-style-type: none"> - Standardization of cut-off values - Validation in prospective, multi-center ACS cohorts
Lipid-Inflammation Ratios				
CHR, NHR, MHR	<ul style="list-style-type: none"> - Combine pro-atherogenic inflammation with anti-atherogenic lipid markers - May reflect residual risk in treated patients 	<ul style="list-style-type: none"> - Dependent on accurate lipid measurements - Not routinely calculated in clinical practice 	<ul style="list-style-type: none"> - Limited validation in acute vs. stable disease - Lack of clinical interpretability guidance 	<ul style="list-style-type: none"> - Integration into composite risk models - Longitudinal studies for prognostic validation
Lipid Biomarkers				
Lipoprotein(a)	<ul style="list-style-type: none"> - Genetically determined - It is mostly genetically determined (70-90%) - Although not routinely performed in clinical practice, Lp(a) testing is becoming increasingly 	<ul style="list-style-type: none"> - Limited acute-phase relevance - Due to acute-phase elevation, Lp(a) should not be measured during ACS, but assessment at discharge or early follow-up is valuable for risk stratification - Testing not routinely 	<ul style="list-style-type: none"> - Role in acute settings underexplored - Absence of standardized screening criteria - Educational gaps among clinicians - Long-term safety and 	<ul style="list-style-type: none"> - Evaluation of new therapeutic agents - Risk stratification in primary prevention - Universal screening for Lp(a) has been recently adopted in Poland through the My Health

	accessible - Independent predictor of long-term CV risk - May indicate inherited risk	available, - Treatment options evolving	therapy monitoring remain undefined	program, which includes cascade testing of young adults to identify affected family members.
Emerging Composite Indices				
SII, SIRI	- Integrate multiple immune pathways - May offer superior predictive value over single indices	- Complex calculation - Not routinely included in lab reports	- Limited large-scale validation - Unclear clinical applicability in ACS	- Prospective cohort studies - Comparative effectiveness research with traditional markers

Abbreviations : CBC – complete blood count; ACS- acute coronary syndrome; WBC: white blood cell count; NLR – neutrophil to lymphocyte ratio; PLR – platelet-to-lymphocyte ratio; MHR - monocyte-to-HDL ratio;; NHR - Neutrophils to HDL-C ratio; CHR- High-sensitivity CRP to HDL-C ratio; SII - systemic immune-inflammation index; SIRI - systemic inflammation response index



Preprint